SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-221651
Filing Date
2020-08-17
Accepted
2020-08-17 06:31:02
Documents
15
Period of Report
2020-08-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d25143d8k.htm   iXBRL 8-K 48765
2 EX-2.1 d25143dex21.htm EX-2.1 465399
3 EX-99.1 d25143dex991.htm EX-99.1 31366
7 GRAPHIC g25143g0817112648351.jpg GRAPHIC 2439
  Complete submission text file 0001193125-20-221651.txt   802810

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA prnb-20200816.xsd EX-101.SCH 3081
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE prnb-20200816_lab.xml EX-101.LAB 18122
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prnb-20200816_pre.xml EX-101.PRE 11412
8 EXTRACTED XBRL INSTANCE DOCUMENT d25143d8k_htm.xml XML 3366
Mailing Address 220 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 220 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-7700
Principia Biopharma Inc. (Filer) CIK: 0001510487 (see all company filings)

IRS No.: 263487603 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38653 | Film No.: 201107893
SIC: 2834 Pharmaceutical Preparations